目的 探討曲安奈德注射液聯(lián)合七葉洋地黃雙苷滴眼液治療滲出型老年性黃斑變性的臨床療效。方法 選取2016年3月-2017年3月在湖南省軍區(qū)機(jī)關(guān)醫(yī)院進(jìn)行治療的滲出型老年性黃斑變性患者86例為研究對(duì)象，根據(jù)接受治療的先后順序分為對(duì)照組和治療組，每組各43例。對(duì)照組在眼結(jié)膜囊內(nèi)滴入七葉洋地黃雙苷滴眼液，1滴/次，3次/d。治療組在對(duì)照組基礎(chǔ)上給予曲安奈德注射液，0.5 mL緩慢注入玻璃腔內(nèi)，1次/周。兩組患均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組的視力、眼底、臨床癥狀評(píng)分、視網(wǎng)膜中央動(dòng)脈血流、超氧化物歧化酶（SOD）和丙二醛（MDA）的情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為74.42%、90.70%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組視力明顯上升，而眼底出血面積、眼底滲出面積、眼底玻璃膜疣面積、黃斑部視網(wǎng)膜厚度均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組納呆、倦怠乏力、胸悶、視物模糊評(píng)分明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組視網(wǎng)膜中央動(dòng)脈收縮期峰值血流速度（PSV）、舒張末期血流速度（EDV）明顯升高，而血管阻力指數(shù)（RI）明顯下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組SOD水平顯著升高，而MDA水平顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 曲安奈德注射液聯(lián)合七葉洋地黃雙苷滴眼液治療滲出型老年性黃斑變性具有較好的臨床療效，可明顯改善患者臨床癥狀，提高視力，減少眼底出血和滲出面積，改善網(wǎng)膜中央動(dòng)脈血流、SOD和MDA，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Triamcinolone Acetonide Injection combined with Esculin and Digitalisglycosides Eye Drops in treatment of exudative age-related macular degeneration. Methods Patients (86 cases) with cerebral infarction in Hunan Military Area Command Hospital from March 2016 to March 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were dropped into the conjunctival sac with Esculin and Digitalisglycosides Eye Drops, 1 drop/time, three times daily. Patients in the treatment group were given Triamcinolone Acetonide Injection on the basis of the control group, 0.5 mL injected into the glass cavity slowly, once weekly. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and vision, fundus, clinical symptom score, central retinal artery blood flow, SOD, and MDA level in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.42% and 90.70%, respectively, and there was difference between two groups (P<0.05). After treatment, the vision in two groups were significantly increased, but the area of fundus hemorrhage, fundus effusion, fundus film, and the thickness of macular retina in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the scores of anorexia, fatigue, chest tightness, and blurred vision in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, PSV and EDV in two groups were significantly increased, but the RI in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of SOD in two groups were significantly increased, but the levels of MDA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Triamcinolone Acetonide Injection combined with Esculin and Digitalisglycosides Eye Drops has clinical curative effect in treatment of exudative age-related macular degeneration, can significantly improve clinical symptom and visual acuity, reduce fundus hemorrhage and effusion area, improve central retinal artery blood flow, SOD and MDA, which has a certain clinical application value.